Introduction
============

The experience of trauma can have a pronounced negative impact on mental health, eliciting various forms of psychopathology. The most common sequelae of trauma are posttraumatic stress disorder (PTSD) and major depressive disorder (MDD).^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4],\ [@bib5]^ It is unclear how trauma elicits these disorders; however, recent evidence from animal models and human clinical studies suggests that changes to DNA methylation resulting from trauma may be one such mechanism.^[@bib6],\ [@bib7],\ [@bib8],\ [@bib9]^

Epigenetics of PTSD and depression
----------------------------------

The majority of methylation studies of PTSD have focused on candidate genes selected on the basis of animal models studies (for example, glucocorticoid receptor (*NR3C1*;^[@bib10],\ [@bib11]^) or genetic association findings, such as *FKBP5*,^[@bib12],\ [@bib13]^ *SLC6A4*,^[@bib14],\ [@bib15]^ *BDNF*^[@bib16]^ and *ADCYAP1*.^[@bib17]^ Differential methylation regions within these candidate genes were also found to be associated with MDD (for example, refs [@bib18], [@bib19], [@bib20], [@bib21], [@bib22]), which is expected given their shared risk factors. Because knowledge about the etiology of PTSD and MDD is limited, the preferred method of explicating the genetic architectures underlying these disorders is the Epigenome Wide Association Study (EWAS) design. The EWAS design allows for a thorough investigation of the epigenetic patterns without relying on *a priori* knowledge of genetic risk factors.^[@bib23],\ [@bib24]^

PTSD EWAS findings
------------------

To date, there are three microarray-based EWAS examining epigenetic patterns in peripheral blood of cases with PTSD compared to trauma-exposed controls. First, Uddin *et al.*^[@bib25]^ investigated methylation profiles of 100 participants (23 with lifetime PTSD). The study found that genes involved in the immune system were more likely to be un-methylated among individuals with PTSD. Second, Smith *et al.*^[@bib26]^ found an overall increased level of methylation in PTSD in a sample of 110 participants (50 with current PTSD). The authors also reported differential methylation of five genes previously associated with inflammation (*TPR, CLEC9A,* ANAPC5*, ANXA2* and *TLR8*). Third, Mehta *et al.*^[@bib27]^ examined methylation profiles of 169 trauma-exposed participants (61 with current PTSD). PTSD was associated with methylation alterations that were in turn linked to gene expression differences in central nervous system development, apoptosis and growth rate networks. A comprehensive review of DNA methylation findings in PTSD can be found elsewhere.^[@bib28],\ [@bib29]^ Overall, the most promising results from human epigenetic studies of PTSD suggest methylation differences in immune function genes in cells of peripheral blood. However, the specific differentially methylated CpG sites identified in each study do not replicate across studies, possibly due to small sample sizes and methodological differences in cohort characteristics, types of trauma and platforms.

Depression EWAS findings
------------------------

Candidate gene studies of MDD have reported differential methylation of specific genes including NR3C1, BDNF and SLC6A4 (for review see Januar *et al.*^[@bib30]^). Seven EWAS of depression have been conducted. However, only two studies had samples of more than 100 participants: Nagy *et al.*^[@bib31]^ analyzed methylation differences in post-mortem prefrontal cortex samples from 76 depressed individuals who committed suicide and 45 healthy controls. They found 115 differentially methylated regions, including regions related to astrocytic function, such as GRIK2 (glutamate receptor, ionotropic kainate 2) and BEGAIN (brain-enriched guanylate kinase-associated protein). Weder *et al.*^[@bib32]^ conducted EWAS on saliva samples from 94 maltreated children and 94 controls and found that methylation in three genes---GRIN1, ID3 and TPPP---was correlated with depression symptoms. Their study also confirmed several candidate genes, including BDNF, NR3C1, and FKBP5. Among the 5 small N EWAS, 3 identified additional differentially methylated genes,^[@bib33],\ [@bib34],\ [@bib35]^ although Sabunciyan *et al.* (2012)^[@bib35]^ were unable to confirm their findings in an independent cohort; and 2 studies found global methylation level differences but no significant results for specific genes.^[@bib36],\ [@bib37]^ Importantly, EWA studies of MDD to date used a variety of tissue sources (post-mortem brain, saliva or blood), which might be one of the reasons, alongside differences in cohort characteristics, why differentially methylated CpG do not replicate across studies.

Limitations of PTSD and MDD EWAS
--------------------------------

Overall, the EWAS approach has provided potentially promising insights into the pathophysiology of both PTSD and MDD, although to date, few if any results have been independently confirmed. Importantly, failure to replicate might also have occurred because EWA studies of depression have not controlled for exposure to extreme stressors, potent triggers of depression^[@bib38],\ [@bib39]^ (although Dempster *et al.*^[@bib34]^ reported the same number of stressful life events in cases and controls). EWAS of PTSD and MDD also have not corrected for differences in the proportion of cell types within the tissue sample interrogated. This is particularly problematic in studies of whole blood, as specific regions of variable DNA methylation are responsible for defining cell lineage, and thus cell heterogeneity may act as a confounder when measuring DNA methylation in samples of peripheral blood without proper adjustment for differential cell counts.^[@bib40],\ [@bib41]^

Current study
-------------

Our study was designed to address the aforementioned limitations. We conducted two EWA analyses of DNA derived from peripheral blood to identify DNA methylation differences associated with PTSD and with MDD respectively, allowing us to test hypothesized genes (15 genes that emerged in previous literature are listed in [Table 1](#tbl1){ref-type="table"}) and investigate novel ones. We used the state-of-the-art 450k DNA methylation array and recruited a large sample (*n*=473) directly exposed to the 11 September 2001 World Trade Center (WTC) disaster. The current study contains the largest sample size to date for PTSD and MDD EWAS and to our knowledge, is the first to study methylation patterns that emerge for these conditions side by side. Finally, we used methylation findings to identify biological pathways that characterize PTSD and MDD. Cellular processes are regulated by a set of genes working in concert; thus biological pathway analysis has emerged as an important and perhaps more biologically valid approach for interpreting results from large-scale EWAS.

Materials and methods
=====================

Participants
------------

Participants were recruited through the Stony Brook WTC-Health Program, part of a consortium of Clinical Centers of Excellence in the New York metropolitan area established in 2002 to monitor and treat WTC-related conditions in responders to the WTC disaster.^[@bib42]^ Enrollees with documented WTC experience were enlisted from extensive outreach efforts involving partnerships with volunteer organizations, labor unions and public outlets. The current study was approved annually by the Committees on Research Involving Human Subjects at Stony Brook University (IRB number: 604113). Written informed consent was obtained.

The sample consisted of 473 responders assessed between February, 2012 and March, 2014. All participants provided blood samples for the epigenetics assays. Inclusion criteria were signed informed consent, sufficient English language skills to participate in a diagnostic interview, and being male. We included only males because females show notably different methylation patterns from males, and the cohort monitored at the Stony Brook WTC clinic is \>90% male. We oversampled individuals with PTSD in order to have sufficient power for planned analyses. Participants were 49.5 years of age on average, predominantly Caucasian (\>80%), and had similar rates of current PTSD and MDD ([Table 2](#tbl2){ref-type="table"}).

Clinical assessment
-------------------

Master's level clinical assessors were trained to administer the PTSD and MDD modules of the Structured Clinical Interview for DSM-IV (SCID^[@bib43]^) with interval instructions (that is, worst episode of symptoms since 11 September 2001). SCID items were modified to assess PTSD symptoms in relation to traumatic WTC exposures (Criterion A). Before conducting the assessment, the interviewers reviewed participants' occupational and medical histories in order to facilitate rapport and enhance the accuracy of interpretation of responses. Inter-rater agreement for 55 independently rated audio-tapes was very good (kappa≥0.82). Diagnoses were coded as (a) currently meets criteria for the disorder (current group), (b) met criteria since 11 September 2001 but does not meet currently (past group), and (c) did not meet criteria since 11 September 2001 (never group). Primary EWA analyses compared responders with current WTC-related PTSD to responders who never developed WTC-PTSD; these analyses were repeated for current MDD versus no MDD.

Illumina infinium human methylation 450K beadchip
-------------------------------------------------

Blood samples were obtained from each participant via venipuncture and sent to Roswell Park Cancer Institute for DNA extraction. Genomic DNA was isolated from 0.3 ml of whole blood using the Qiagen BioRobot Universal System and the QIAamp DNA blood BioRobot MDx Kit (Qiagen, Valencia, CA, USA) following the manufacturer's recommended protocol. DNA methylation profiling was performed by Roswell Park Cancer Institute using the Human Methylation 450 K BeadChip (Illumina, San Diego, CA, USA). DNA extraction and methylation profiling were done blinded to group assignment. Five hundred nanogram of high-quality genomic DNA measured by picogreen quantitation (Life technologies, Grand Island, NY, USA) was bisulphite converted, amplified, fragmented and hybridized to the Illumina Infinium Human Methylation 450 K Beadchip using standard Illumina protocol. Data were processed using Illumina\'s GenomeStudio methylation module (v1.9.0).

Data pre-processing and normalization
-------------------------------------

The 450K BeadChip methylation data from the GenomeStudio were imported into R (<http://cran.r-project.org>). The methylation data at each CpG probe were represented as a beta (*β*) values, that is, the ratio of methylated probe intensities to the total probe intensities. Pre-processing of methylation data at the 485 557 CpG probes was performed as follows. Probes with detection *P*-value \>0.001 were set to missing, and probes with more than 20% missing were filtered. Beta mixture quantile (BMIQ) normalization^[@bib44]^ was applied to the beta values for correction of bias due to the type I and type II probes. Non-specific, cross-hybridized probes,^[@bib45],\ [@bib46]^ probes overlapping with a single-nucleotide polymorphism, and probes mapping to repeat regions were filtered. The final data consisted of 375 223 CpG sites and 473 samples.

Estimation of blood cell type proportions
-----------------------------------------

Cell type proportions have been implicated in DNA methylation analysis of whole blood samples.^[@bib40],\ [@bib47]^ The proportions of CD8T, CD4T, natural killer (NK), Bcell, monocytes (Mono) and granulocytes (Gran) were estimated using the R packages minfi and FlowSorted.Blood.450 based on the procedures described previously.^[@bib40]^ We normalized the sum of the proportions per sample to one, and included five (CD8T, CD4T, NK, Bcell and Mono) out of six estimated cell types as an adjustment factor in our EWAS analysis. The association between each cell type and phenotype, adjusting for age, smoking status and race (Caucasian vs non-Caucasian), was carried out using linear regression.

Estimation of population stratification
---------------------------------------

Population stratification was estimated using the principal component approach based on the annotation file of autosomal CpG sites, which were within 10 bps of a variant identified in the 1000 Genome Project (Phase 1) with MAF\>0.01.^[@bib48]^

Statistical method for EWA analyses
-----------------------------------

To identify CpG sites associated with each phenotype, separate linear regression for each CpG was first fitted on logit transformed beta values (log(*β*/(1−*β*))) as response and diagnosis (current vs never), adjusting for age, smoking status, race, and cell types. We also compared the results by adjusting for first (1) 2 and (2) 10 estimated population stratification principal components instead of race in our model. The logit transformed *β* values, also known as the M-values, had been recommended for conducting differential methylation analysis.^[@bib49],\ [@bib50]^ A false discovery rate (FDR)^[@bib51]^ was used to account for multiple testing. *Post hoc* analysis was carried out to examine whether the past PTSD (MDD) group show differential methylation patterns on candidate CpG sites in comparison to methylation values of current and never groups. Principal component method was used to reduce the multiple candidate CpG sites into a single eigen CpG. The *P*-values for the *post hoc* comparison were computed from two-tailed two sample *t*-tests. Global methylation level was defined as the average methylation (beta values averaged over all the CpG sites). We also considered the average methylation defined by the beta values averaged over the 22 622 CpG sites which overlapped with the Infinium HumanMethylation27 Beadchip. The *P*-values for comparison of global methylation level were computed from two-tailed two sample *t*-tests. The effect of WTC exposures^[@bib3]^ on the EWA analyses were also examined ([Supplementary Materials](#sup1){ref-type="supplementary-material"}), but did not change the results in a way that would alter the interpretation.

Pathway and gene ontology analyses
----------------------------------

Pathway and gene ontology analyses were carried out using the gometh function in the Bioconductor package missMethyl.^[@bib52]^ Since the number of CpG sites mapping to each gene varied in the Methylation 450 K BeadChip, pathway and gene ontology analysis would be biased and inaccurate.^[@bib53]^ gometh accounted for the varying number of CpG sites per gene by providing a prior probability for each gene based on gene length, followed by a modified hypergeometric test for over-representation of a gene set.^[@bib54]^ We tested for over-representation among the top 100 to 500 (in increment of 50) CpG sites for each analysis, against the background list of 375 223 CpG sites. In all, 5776 gene ontologies including biological processes, molecular functions and cellular components, and 290 KEGG pathways (minimum and maximum number of genes for each gene set were 15 and 500, respectively) were tested. Overlapping gene sets significant at FDR 0.05 for all the top K CpG sites were reported.

Data availability
-----------------

The methylation data is available at the Psychiatric Genomics Consortium (PGC) website <https://www.med.unc.edu/pgc/>.

Results
=======

EWAS analyses
-------------

EWAS analyses with each diagnostic group did not identify statistically significant CpG sites at FDR 0.05. The list of CpG sites at a nominal *P*-value 0.0001 that did not reach a significant FDR cutoff is provided in [Table 3](#tbl3){ref-type="table"}. The signs of the estimated coefficients remain consistent within the subset analysis, that is, PTSD case vs control within never MDD and MDD case vs control within current PTSD. The top suggestive CpG for PTSD was cg05693864 at gene body of ZDHHC11, with the mean methylation difference between current and never groups of 2.7%. The top suggestive CpG for MDD was cg19722082 on EDIL3 gene (−2.5% mean methylation difference). Only three CpG sites common to both PTSD and MDD emerged at the suggestive level. The most prominent of them was cg06182923, located on the gene body of CSMD2 (−3.1% in PTSD and −3.5% in MDD). Due to the high correlation between the estimated cell type proportions and the population stratification principal components, our primary analyses were based on a model which adjusted for age, smoking status, race and cell types ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Additional details on the secondary analyses based on a model which adjusted for population stratification principal components were provided in [Supplementary Materials](#sup1){ref-type="supplementary-material"}.

Principal component analyses were performed on the list of CpG sites at nominal *P*-value 0.0001 for each of PTSD and MDD. The methylation profiles were represented using the first principal component, that is, the eigen CpG. [Figure 1](#fig1){ref-type="fig"} compares the eigen CpG for current, past and never groups of PTSD and MDD. The past PTSD group exhibited intermediate eigen CpG values (*P*=1.12e−05 for current vs past, *P*=0.00331 for past vs never), suggesting that the overall methylation profiles of the top ranking CpG sites were associated with disease progression. For MDD, the past group was not statistically different from the never group (*P*=0.0902), whereas the current was statistically different from the past group (*P*=0.00915).

Of note, none of CpG sites mapping on the previously identified candidate genes (*FKBP5*, *NR3C1*, *BDNF*, *SLC6A4*, *ADCYAP1*, *TPR*, *CLEC9A*, *ANAPC5*, *ANXA2*, *TLR8*, *GRIK2*, *BEGAIN*, *GRIN1*, *ID3* and *TPPP*) was significant at nominal *P*-value.0001. To evaluate any trends in these genes, we examined the direction of methylation on CpG sites that exhibited differential methylation between current and never groups at nominal *P*-value⩽0.05 ([Table 1](#tbl1){ref-type="table"}). These CpG sites were mostly hypomethylated in PTSD and MDD. One study^[@bib26]^ observed a higher average methylation level in PTSD relative to non-PTSD based on the Infinium HumanMethylation27 Beadchip. However, our global methylation pattern (defined using either all CpG sites or CpG sites which overlapped with the Infinium HumanMethylation27 Beadchip) did not show a statistically significant difference (*P*-value=0.589 and 0.884, respectively) comparing current PTSD to control. The *P*-values were 0.911 (all CpG sites) and 0.942 (Infinium HumanMethylation27 CpG sites) comparing current MDD to control.

Pathway and gene ontology analyses
----------------------------------

Twenty-three KEGG pathways were significant at FDR 0.05 for PTSD, and two were significant for MDD ([Table 4](#tbl4){ref-type="table"}). The top KEGG pathways that emerged for PTSD included cGMP-PKG, oxytocin and MAPK signaling, insulin resistance, cholinergic synapse and inflammatory bowel disease pathways. The two KEGG pathways that emerged for MDD are implicated in phosphatidylinositol signaling system and cell cycle. No gene ontologies were enriched at FDR 0.05 for both PTSD and MDD. The results of the cell type proportion analyses are presented in [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}. In addition, both the results from EWAS and pathway analyses remained consistent after taking into account potential confounding due to exposure ([Supplementary Materials](#sup1){ref-type="supplementary-material"}).

Discussion
==========

The current study reports results from the largest EWA analyses of PTSD and of MDD to date, investigating DNA methylation differences underpinning these two conditions. We found no significant genome-wide methylation differences between responders with current versus no WTC-related disorder, suggesting that links between individual methylation sites and these conditions are too subtle to be detected in such a sample. However, we identified disorder-specific biological pathways underpinned by differentially methylated genes. PTSD was associated with pathways regulating neuron signaling, inflammation and multiple aspects of physical health. The current study makes an important contribution to the understanding of methylation in PTSD and in MDD, evaluating hypotheses that emerged in research on these phenotypes.

EWAS findings
-------------

Our null findings are in contrast to previously published EWAS results of PTSD and depression. Using a much larger sample than previous studies, we did not confirm the genes implicated in prior studies of DNA methylation in PTSD or MDD. Previous work has suggested that differentially methylated sites were significantly overrepresented in immune system genes for both disorders. However, no individual immune system gene was identified in this study. Also, we did not observe statistically significant methylation differences in 15 candidate genes identified by prior studies. Furthermore, analyses of trends suggested hypomethylation of FKBP5, NR3C1, BDNF and SLC6A4 in PTSD and MDD, whereas prior studies found hypermethylation in NR3C1, BDNF and SLC6A4,^[@bib15],\ [@bib30],\ [@bib55],\ [@bib56]^ raising questions about their role in the methylation signature of PTSD and MDD.

Methodological differences between our study and previous EWA studies might account for some of the discrepancies in the results, and as such our findings need to be considered in the context of the current sample characteristics (especially gender composition) as well as methodology. First, our study focused on men, while previous studies included more women than men. Growing literature demonstrates that DNA methylation changes occur in a sex-specific manner.^[@bib57]^ Second, previous PTSD EWA studies were performed on populations that were predominantly of African American ancestry, while our sample is mostly of European American ancestry. Recent reports have found significant differences in DNA methylation between African American and Caucasian ancestry subjects. This suggests that ancestry-specific genetic background may play a role in shaping the epigenetic landscape of the human genome in ways similar to SNP-GWAS population stratification.^[@bib48]^ Third, trauma exposure in our study was a specific event common to all responders---the WTC disaster. Previous studies considered retrospectively reported traumas that were not common to all individuals and were uncorroborated.^[@bib58],\ [@bib59],\ [@bib60]^

Fourth, previous EWAS of MDD used a variety of tissue sources, with only one study^[@bib33]^ using blood. Fifth, previous EWAS of MDD did not consider trauma-exposed populations, which might be a subgroup characterized by somewhat different depression etiology.^[@bib58],\ [@bib59],\ [@bib60]^ Finally, prior studies did not control for blood cell types. This is particularly problematic because findings in PTSD of differential methylation amongst genes involved in immune response could represent greater number of immune cells in the blood sample. Controlling for differences in the number of immune cells likely affects the ability to detect these differences. Overall, each study to date, including the current study, applied different methodologies and thus cannot be considered as direct replications of one another.

Biological pathways
-------------------

We also conducted pathway analyses in the current sample in order to identify significantly enriched gene sets associated with PTSD and MDD. PTSD was characterized by a wide range of pathways, many of which map onto the biological mechanisms implicated by previous methylation studies of PTSD. First, the cGMP-PKG signaling pathway has been identified as the top KEGG pathway for PTSD, which was shown to regulate synaptic plasticity and fear memory consolidation in the lateral amygdala.^[@bib61]^ The second most significant pathway for PTSD was oxytocin signaling. Neuropeptide oxytocin has been shown to be an important anti-stress factor of the brain^[@bib62]^ and implicated in PTSD.^[@bib63],\ [@bib64]^ Third, we identified several pathways related to immunity (for example, inflammatory bowel disease and rheumatoid arthritis pathways), which is in line with a large body of evidence that PTSD is associated with altered inflammatory processes.^[@bib65],\ [@bib66],\ [@bib67]^ Several genes (most notably FKBP5) are thought to play a role in regulation of the HPA axis and immunological responses to stress.^[@bib13],\ [@bib68],\ [@bib69]^ Although the current study has not confirmed differential methylation of these individual genes, the observed immunity-related pathways are consistent with previous research. Fourth, several cancer-related pathways (for example, MAPK signaling pathway), as well as pathways related to cardiovascular and metabolic disease (for example, insulin resistance pathway) and the nervous system (for example, cholinergic synapse pathway) emerged for PTSD, which are in line with the considerable co-occurrence of PTSD with a range of physical disorders.^[@bib3],\ [@bib70],\ [@bib71],\ [@bib72]^

Conversely, only two pathways emerged for MDD. First, phosphatidylinositol signaling system was identified as the top significant KEGG pathway. The phosphatidylinositol signaling system has broad physiological significance, and has been shown to be affected by antidepressants in several studies.^[@bib73],\ [@bib74],\ [@bib75],\ [@bib76]^ The second pathway significant in MDD was cell cycle, a broad pathway without specific links to depression. It is possible that the smaller number of MDD cases resulted in lower power to detect significant MDD pathways.

Limitations
-----------

The current study had several strengths, including the largest EWAS sample to date in research on PTSD and MDD, and exposure to a common traumatic even for all participants. Nonetheless, our findings must be considered in the context of several limitations. First, since our study is cross-sectional, we cannot determine whether observed alterations in the epigenome of PTSD affected patients are a consequence of the disease or a part of its etiology. By identifying a trauma-exposed, unaffected comparison group, we guarded against differential methylation being just a consequence of trauma exposure. Second, the sample size of our study is relatively small for EWAS, even if it is the largest among PTSD and MDD methylation studies.^[@bib77],\ [@bib78]^ Third, our methylation analysis was performed in DNA samples derived from peripheral blood cells and were thus a mix of cell types. We sought to control for the mix statistically, which emerged as the state-of-the-art method, but future work needs to isolate and examine each cell type individually. Fourth, as discussed above, sample characteristics, tissue used and other methodological aspects of the current study differed substantially from previous EWAS of PTSD and MDD. In particular, we focused on males while prior studies relied on predominantly female samples. Larger samples are needed to investigate the impact of gender differences on methylation in PTSD, an important open question. Future studies designed as direct replications of prior research need to be conducted, ideally using large sample sizes, to confirm previous findings. Finally, a stronger association between methylation and diagnoses could potentially be derived by considering allele specific methylation as observed in Klengel *et al.*^[@bib13]^ or by also considering lifetime disorders not associated with 9/11.

Conclusions
===========

The current study aimed to provide a better understanding of the relationship between epigenetic alteration and PTSD and MDD. We found no epigenome-wide significant hits for either condition, and as such did not confirm findings from previous, smaller EWAS and candidate gene studies of PTSD and MDD. Nonetheless, we identified enriched gene sets involved in several biological pathways associated with PTSD, including stress response, inflammation, neural signaling and physical health.
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###### 

Click here for additional data file.

![Boxplots comparing the first principal component computed on 7 and 27 CpG sites at nominal *P*-value 0.0001 for (**a**) PTSD and (**b**) MDD, respectively. The *P*-values were computed from two-tailed two sample *t*-tests. MDD, major depressive disorder; PTSD, posttraumatic stress disorder.](tp2017130f1){#fig1}

###### Comparison of CpG sites mapping to reported genes in PTSD and MDD literatures

  *Gene*      *PTSD*   *MDD*                   
  ----------- -------- ------- --- --- --- --- -------------------------------------------------------------------------------
  *FKBP5*     1        1       0   1   1   0   Binder *et al.*^[@bib12]^ Klengel *et al.*^[@bib13]^ Weder *et al.*^[@bib32]^
  *NR3C1*     1        1       0   6   6   0   McGowan *et al.*^[@bib10]^ Yehuda *et al.*^[@bib11]^ Weder *et al.*^[@bib32]^
  *BDNF*      4        3       1   2   2   0   Roth *et al.*^[@bib16]^ Weder *et al.*^[@bib32]^
  *SLC6A4*    0        0       0   1   1   0   Chang *et al.*^[@bib14]^ Koenen *et al.*^[@bib15]^
  *TPR*       0        0       0   0   0   0   Smith *et al.*^[@bib26]^
  *CLEC9A*    0        0       0   0   0   0   Smith *et al.*^[@bib26]^
  *ANAPC5*    0        0       0   0   0   0   Smith *et al.*^[@bib26]^
  *ANXA2*     1        1       0   2   2   0   Smith *et al.*^[@bib26]^
  *TLR8*      1        0       1   0   0   0   Smith *et al.*^[@bib26]^
  *GRIK2*     0        0       0   2   2   0   Nagy *et al.*^[@bib31]^
  *BEGAIN*    0        0       0   0   0   0   Nagy *et al.*^[@bib31]^
  *GRIN1*     0        0       0   2   0   2   Weder *et al.*^[@bib32]^
  *ID3*       0        0       0   0   0   0   Weder *et al.*^[@bib32]^
  *TPPP*      0        0       0   2   0   2   Weder *et al.*^[@bib32]^
  *ADCYAP1*   3        2       1   2   2   0   Ressler *et al.*^[@bib17]^

Abbreviations: Hyper, hypermethylation in case relative to control; Hypo, hypomethylation in case relative to control; MDD, major depressive disorder; PTSD, posttraumatic stress disorder. *N,* number of CpG sites at nominal *P*⩽0.05.

###### Clinical characteristics of PTSD and MDD samples. Mean (s.d.) were reported for Age

  *PTSD*       *Current (Case)* n=*171*   *Past* n=*100*   *Never (Control)* n=*202*   P*-value*
  ------------ -------------------------- ---------------- --------------------------- -----------
  Age          49.5 (7.6)                 48.3 (7.8)       50.0 (8.4)                  0.504
                                                                                       
  *Race*                                                                               
   Caucasian   139 (81.3)                 78 (78.0)        165 (81.7)                  1
   Other       32 (18.7)                  22 (22.0)        37 (18.2)                    
                                                                                        
  *Smoker*                                                                             
   Yes         28 (16.4)                  10 (10.0)        9 (4.5)                     \<0.01
   No          143 (83.6)                 90 (90.0)        193 (95.5)                   

  *MDD*[a](#t2-fn3){ref-type="fn"}   *Current (Case)* n=*116*   *Past* n=*60*   *Never (Control)* n=*282*   P*-value*
  ---------------------------------- -------------------------- --------------- --------------------------- -----------
  Age                                50.0 (8.0)                 49.2 (8.2)      49.2 (8.0)                  0.433
                                                                                                             
  *Race*                                                                                                    
   Caucasian                         94 (81.0)                  46 (76.7)       230 (81.6)                  1
   Other                             22 (19.0)                  14 (23.3)       52 (18.4)                    
                                                                                                             
  *Smoker*                                                                                                  
   Yes                               18 (15.5)                  11 (18.3)       18 (6.4)                    \<0.01
   No                                98 (84.5)                  49 (81.7)       264 (93.6)                   

Abbreviations: MDD, major depressive disorder; PTSD, posttraumatic stress disorder.

Number (%) were reported for Race and Smoker within each group. The *P*-values were computed from *t*-test (for Age) and *χ*^2^-test (for Race, Smoker and PTSD and MDD comorbidity) comparing current to control. PTSD and MDD cases correspond to current PTSD and current MDD, respectively.

MDD for 15 patients were not recorded.

###### Top ranking CpG sites for PTSD and MDD and at nominal *P*-value 0.0001

  *CpG*         *Chromosome*   *Location*   *Gene*         *Location*   *Diff*     *Coef*   *PV*
  ------------- -------------- ------------ -------------- ------------ ---------- -------- ----------
  *PTSD*                                                                                    
   cg05693864   5              844184       ZDHHC11        Body         0.027      0.25     1.73E−06
   cg06182923   1              33985406     CSMD2          Body         −0.0312    −0.143   4.73E−05
   cg08696494   20             61447272     COL9A3         TSS1500      0.0153     0.0765   5.39E−05
   cg25664402   1              244013908    Intergenic     Intergenic   −0.00602   −0.146   5.80E−05
   cg05569176   3              33841973     PDCD6IP        Body         0.0129     0.164    7.82E−05
   cg09370982   16             2547559      TBC1D24        Body         0.00326    0.21     8.97E−05
   cg07654569   8              79577796     FAM164A        TSS1500      −0.0184    −0.311   9.91E−05
                                                                                             
  *MDD*                                                                                     
   cg19722082   5              83681563     EDIL3          TSS1500      −0.0253    −0.215   1.63E−06
   cg01145119   8              144441955    Intergenic     Intergenic   0.0199     0.0843   2.16E−06
   cg18155359   1              39663908     MACF1          Body         0.00849    0.602    1.67E−05
   cg08843623   16             85627648     Intergenic     Intergenic   0.0244     0.0934   2.14E−05
   cg22058452   2              95662214     Intergenic     Intergenic   0.0038     0.674    2.73E−05
   cg23606623   17             79373017     BAHCC1         TSS1500      −0.00566   −0.198   2.87E−05
   cg27081103   16             3241159      Intergenic     Intergenic   −0.00956   −0.238   3.21E−05
   cg06182923   1              33985406     CSMD2          Body         −0.0347    −0.154   3.28E−05
   cg08059112   19             2294887      LINGO3         5\'UTR       0.0153     0.0672   3.71E−05
   cg02798899   12             125028166    Intergenic     Intergenic   0.0161     0.0908   4.47E−05
   cg18074834   7              143085529    ZYX            Body         0.0114     0.0514   4.47E−05
   cg04654716   5              74162924     FAM169A        TSS1500      0.0112     0.0503   4.55E−05
   cg15727507   17             80981575     B3GNTL1        Body         0.0164     0.0669   4.78E−05
   cg05693864   5              844184       ZDHHC11        Body         0.0233     0.226    5.42E−05
   cg08696494   20             61447272     COL9A3         TSS1500      0.0178     0.081    5.74E−05
   cg25810455   13             103253707    TPP2           Body         0.00448    0.957    5.82E−05
   cg03710029   17             79265601     SLC38A10       Body         0.0153     0.063    5.87E−05
   cg26628751   17             80981644     B3GNTL1        Body         0.0196     0.0736   5.94E−05
   cg04854089   11             46355137     DGKZ           Body         0.0106     0.137    6.59E−05
   cg16657453   17             17735704     SREBF1         Body         0.00563    0.454    6.88E−05
   cg07970325   6              106497542    Intergenic     Intergenic   0.0119     0.0535   7.22E−05
   cg12033248   8              36763165     KCNU1          Body         −0.00818   −0.245   8.29E−05
   cg21429107   8              144790317    LOC100130274   TSS200       0.0262     0.132    8.43E−05
   cg16371598   X              72433997     NAP1L2         1stExon      −0.00682   −0.238   8.77E−05
   cg09664445   17             2612406      KIAA0664       5\'UTR       0.0124     0.0507   8.86E−05
   cg23606775   1              9790616      CLSTN1         Body         0.0132     0.0559   9.70E−05
   cg01604412   12             132663741    Intergenic     Intergenic   0.0167     0.0727   9.83E−05

Abbreviations: MDD, major depressive disorder; PTSD, posttraumatic stress disorder.

Columns 4--6 report the beta difference between case and control, estimated coefficient and estimated *P*-values, respectively. The CpG annotation was obtained from Bionconductor package IlluminaHumanMethylation450kanno.ilmn12.hg19 based on Infinium Human Methylation450K manifest.

###### List of significant KEGG pathways (FDR\<0.05) for PTSD and MDD among the top 100 CpG sites

  *Pathway*                                               N     *DE*   *FDR*      *Genes*
  ------------------------------------------------------- ----- ------ ---------- --------------------------------------
  *PTSD*                                                                          
   cGMP-PKG signaling pathway                             167   5      0.000481   *ADCY3;MEF2C;NFATC1;PIK3R2;CACNA1D*
   Oxytocin signaling pathway                             158   5      0.000481   *ADCY3;MEF2C;NFATC1;PIK3R2;CACNA1D*
   AGE-RAGE signaling pathway in diabetic complications   101   4      0.000917   *FIGF;NFATC1;PIK3R2;TGFB3*
   MAPK signaling pathway                                 254   5      0.002      *MEF2C;NFATC1;RPS6KA2;TGFB3;CACNA1D*
   Pantothenate and CoA biosynthesis                      18    2      0.00771    *PANK4;BCAT1*
   cAMP signaling pathway                                 200   4      0.00771    *ADCY3;NFATC1;PIK3R2;CACNA1D*
   Focal adhesion                                         200   4      0.00771    *COL9A3;FIGF;PIK3R2;TNXB*
   Progesterone-mediated oocyte maturation                89    3      0.00771    *ADCY3;PIK3R2;RPS6KA2*
   Dilated cardiomyopathy                                 89    3      0.00868    *ADCY3;TGFB3;CACNA1D*
   Osteoclast differentiation                             125   3      0.00906    *CTSK;NFATC1;PIK3R2*
   HTLV-I infection                                       255   4      0.00906    *ADCY3;NFATC1;PIK3R2;TGFB3*
   Insulin resistance                                     109   3      0.00975    *PIK3R2;RPS6KA2;OGT*
   Cholinergic synapse                                    111   3      0.015      *ADCY3;PIK3R2;CACNA1D*
   Hepatitis B                                            135   3      0.0159     *NFATC1;PIK3R2;TGFB3*
   PI3K-Akt signaling pathway                             324   4      0.0176     *COL9A3;FIGF;PIK3R2;TNXB*
   Adrenergic signaling in cardiomyocytes                 148   3      0.0188     *ADCY3;PIK3R2;CACNA1D*
   Carbohydrate digestion and absorption                  41    2      0.0188     *PIK3R2;CACNA1D*
   Inflammatory bowel disease (IBD)                       63    2      0.033      *NFATC1;TGFB3*
   Pathways in cancer                                     396   4      0.0354     *ADCY3;FIGF;PIK3R2;TGFB3*
   Rap1 signaling pathway                                 212   3      0.0411     *ADCY3;FIGF;PIK3R2*
   Rheumatoid arthritis                                   85    2      0.0411     *CTSK;TGFB3*
   Protein digestion and absorption                       84    2      0.0479     *COL9A3;COL27A1*
   Hypertrophic cardiomyopathy (HCM)                      83    2      0.0489     *TGFB3;CACNA1D*
                                                                                   
  *MDD*                                                                           
   Phosphatidylinositol signaling system                  99    3      0.0425     *INPP5D;DGKZ;MTMR2*
   Cell cycle                                             124   3      0.0425     *MCM2;RAD21;TGFB3*

Abbreviations: FDR, false discovery rate; MDD, major depressive disorder; PTSD, posttraumatic stress disorder. These pathways were also significant when we considered top 150 to 500 CpG sites (increment of 50 CpG sites). N is the size of the pathway, DE is the number of genes in our list overlapping with the pathway, Genes is the list of overlapping genes.
